Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

May 17, 2022
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference
May 16, 2022
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 04, 2022
EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments
May 04, 2022
EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan
Apr 27, 2022
EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

Stern Investor Relations
p. 212.362.1200

Amy Phillips
p. 412.327.9499